Ilya Senatorov, Pharm.D, Ph.D
- Center for Cancer Research
- National Cancer Institute
- Building 37, Room 1066
- Bethesda, MD 20892
- 240.760.6435
- ilya.senatorov@nih.gov
RESEARCH SUMMARY
Dr. Senatorov is a cancer pharmacologist interested in deciphering therapy sensitivity and resistance profiles in prostate cancer across a broad compound library spanning many mechanistic classes. His current research combines high throughput compound screening with transcriptomic analysis for biomarker discovery and generation of prognostic gene signatures predicting response or resistance using patient-derived organoid models.
Areas of Expertise
1) Drug mechanisms of action and resistance, 2) Organoid culturing, 3) Genomic and Transcriptomic Analysis, 4) Gene Signatures
Ilya Senatorov, Pharm.D, Ph.D
Publications
Selected Recent Publications
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
Mol Cancer Ther.
May 27.10.1158/1535-7163:
2021.
[ Journal Article ]
Carboxy-Terminal Phosphoregulation of the Long Splice Isoform of Free-Fatty Acid Receptor-4 Mediates β-Arrestin Recruitment and Signaling to ERK1/2
Mol Pharmacol.
May;97(5):304-313.:
2020.
[ Journal Article ]
The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines
Biochem Pharmacol.
Apr;150:170-180:
2018.
[ Journal Article ]
Free-fatty acid receptor-4 (FFA4) modulates ROS generation and COX-2 expression via the C-terminal β-arrestin phosphosensor in Raw 264.7 macrophages
Biochem Pharmacol.
Dec 15;146:139-150.:
2017.
[ Journal Article ]
Fish oil and flax seed oil supplemented diets increase FFAR4 expression in the rat colon
Inflamm Res.
Oct;64(10):809-815,
2015.
[ Journal Article ]